A Phase 1/1b Study of IAM1363 in HER2 Cancers
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
What the trial team says
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations.
Key facts
- Registry number
- NCT06253871
- Stage of testing
- Phase 1
- Conditions studied
- HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
Where it is running
This trial lists 53 sites.
-
California
- UCSD Moores Cancer Center (La Jolla)
- USC Norris Comprehensive Cancer Center (Los Angeles)
-
Colorado
- University of Colorado Cancer Center (Aurora)
-
Dublin
- The START center Dublin (Dublin)
-
Florida
- University of Miami (Miami)
- Comprehensive Hematology Oncology (St. Petersburg)
-
France
- Centre Georges François Leclerc (Dijon)
- Institut de Cancerologie de l'Ouest (Saint-Herblain)
- Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole Institut Claudius Regaud " (Toulouse)
-
Illinois
- University of Chicago (Chicago)
-
Ireland
- Cork University Hospital, Wilton (Cork)
- St. Vincent's University Hospital (Dublin)
-
Italy
- Azienda Ospedaliero Universitaria Careggi - Largo Giovanni Alessandro Brambilla 3 (Florence)
- Istituto Europeo di Oncologia (IEO) (Milan)
- Grande Ospedale Metropolitano Niguarda (Milan)
- Azienda Ospedaliera Universitaria Luigi Vanvitelli (Naples)
-
Massachusetts
- Massachusetts General Hospital (Boston)
- Dana Farber Cancer Institute (Boston)
-
Michigan
- University of Michigan (Ann Arbor)
- Henry Ford Cancer Institute (Detroit)
- START - Midwest Cancer Research Center (Grand Rapids)
-
Missouri
- Saint Luke's Cancer Institute (Kansas City)
- Washington University School of Medicine (St Louis)
-
Netherlands
- Netherlands Cancer Institute-Antoni van Leeuwenhoek (Amsterdam)
-
New Hampshire
- Dartmouth Hitchcock Medical (Lebanon)
-
New Jersey
- Rutgers Cancer Institute (New Brunswick)
-
New York
- Icahn School of Medicine at Mount Sinai (New York)
-
North Carolina
- Duke Cancer Institute (Durham)
-
Ohio
- University Hospital Cleveland Medical Center (Cleveland)
- Cleveland Clinic (Cleveland)
-
Oklahoma
- OU Health Stephenson Cancer Center (Oklahoma City)
-
Oregon
- Providence Cancer Institute (Portland)
-
South Korea
- Seoul National University Hospital (Seoul)
- Severance Hospital - Yonsei Cancer Center (Seoul)
- Asan Medical Center (Seoul)
- Samsung Medical Center (Seoul)
-
Spain
- Hospital Universitario Vall dHebron (Barcelona)
- Hospital Universitario 12 de Octubre (Madrid)
- START Madrid CIOCC, Hospital Universitario HM Sanchinarro (Madrid)
- Hospital Universitario Regional Málaga (Málaga)
- Hospital Universitario Virgen del Rocio (Seville)
- Hospital Clinico Universitario de Valencia (INCLIVA) (Valencia)
-
Tennessee
- SCRI Oncology Partners (Nashville)
- Vanderbilt Ingram Cancer Center (Nashville)
-
Texas
- NEXT Oncology - Austin (Austin)
- Mary Crowley Cancer Research (Dallas)
- MD Anderson Cancer Center - University of Texas (Houston)
-
United Kingdom
- Royal Marsden NHS Foundation Trust, Royal Marsden Hospital (RMH)/Chelsea) (Chelsea)
- Oxford University Hospitals NHS Foundation Trust Churchill Hospital (Oxford)
- Royal Marsden NHS Foundation Trust, Royal Marsden Hospital (RMH)/Sutton (Sutton)
-
Utah
- START Mountain Region (West Valley City)
-
Virginia
- NEXT Oncology - Virginia Cancer Specialists (Fairfax)
-
Washington
- Fred Hutchinson Cancer Center (Seattle)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.